Potential and promises of phospholipid structured novel formulations for hepatoprotection

International Journal of Drug Development and Research

Volumn 4, Issue 1, 2012, Pages 51-58

  Silki, ^a   Deepak, Kapoor ^b   Sarvesh, Malviya ^b   Vaibhav, Talwar ^a   Prakash, Katare Om ^a  

^a PANJAB UNIVERSITY   (India)

^b Oniosome Healthcare Pvt Ltd   (India)

Author keywords

Hepatoprotection; Hepatotoxicity; Lipid based drug delivery systems; Nanosystems; Phospholipids

Indexed keywords

CUSCUTA CHINENSIS EXTRACT; CYTOCHROME P450; CYTOCHROME P450 2E1; GLYCYRRHETINIC ACID PHOSPHOLIPID COMPLEX; NANOCARRIER; PHOSPHOLIPID;

ABDOMINAL DISCOMFORT; ANOREXIA; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; DRUG STABILITY; DRUG TARGETING; FATIGUE; FATTY LIVER; HEPATITIS; HUMAN; HYDROPHILICITY; INFLAMMATORY CELL; KUPFFER CELL; LIPID PEROXIDATION; LIVER INJURY; LIVER NECROSIS; LIVER PROTECTION; LIVER TOXICITY; MICROEMULSION; NANOEMULSION; NATURAL KILLER CELL; NATURAL KILLER T CELL; NAUSEA; OXIDATIVE STRESS; REVIEW; URINE COLOR;

EID: 84861309031     PISSN: None     EISSN: 09759344     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. BegumTN, Hepatoprotective activity of Azimatetracantha Lam. in experimental animals, Journal of Pharmacy Research, 2011, 4(7): p. 2359-2360.
2. Rubin W, A survey of Chinese herbal ingredients with liver protection activities, Chinese Medicine, 2007, 2 (5).
3. Kaplowitz N, Drug-induced liver disorders: implications for drug development and regulation, Drug Saf, 2001, 24: p. 483-90.
4. Victor J, Drug-Related Hepatotoxicity, The New England Journal of Medicine, 2006, 354: p. 731-739.
5. Mehta N, Drug-Induced Hepatotoxicity, MedScape reference Drugs diseases and procedures, 2010 Apr 26, 2010.
6. Kaplowitz N, Drug-Induced Liver Injury, Clinical Infectious Diseases, 2004, 38(Suppl 2): p. S44-8.
7. Uetrecht J, Knowles S, Shear N, Idiosyncratic drug reactions: the reactive metabolite syndrome, Lancet, 2000, 356: p. 1587-91.
8. Abele U, Habscheid W, Dahm HH, Severe cholestasis with kidney failure from anabolic steroids in a body builder, Dtsch. Med. Wochenschr, 1999, 124: p. 1029-1032.
9. Cynthia J, Michael P Holt, Mechanisms of Drug-Induced Liver Injury, The AAPS Journal, 2006, 8(1).
10. Jaeschke H, Cederbaum AI, Gores GJ, Hinson JA, Pessayre D, Lemasters JJ, Mechanisms of hepatotoxicity, Toxicol Sci., 2002, 65(2): p. 166-76.
11. Roberts L, Patel T, Jones BA, Gores GJ Dysregulation of apoptosis as a mechanism of liver disease: an overview, Semin. Liver Dis., 1998, 18 (2): p. 105-14.
12. Bhawna S, Kumar SU, Hepatoprotective activity of some indigenous plants, Int. J. Pharm. Tech. Res., 2009, 4: p. 1330-1334.
13. Fricker G, Phospholipids and Lipid-Based Formulations in Oral Drug Delivery, Pharm Res, 2010, 27: p. 1469-1486.
14. Gatti G, Perucca E Plasma concentrations of free and conjugated silybin after oral intake of a silybinphosphatidylcholine complex (silipide) in healthy volunteers, Int. J. Clin. Pharmacol. Ther., 1994, 32 (11): p. 614-7.
15. Kimura T, Takeda K, Kageyu A, Toda M, Kurosaki Y, NakayamaT, Intestinal absorption of dolichol from emulsions and liposomes in rats. Chem. Pharm. Bull. (Tokyo), 1989, 37 (2): p. 463-6.
16. Singh D, Rawat MS, Semalty A, Semalty M, Quercetin-Phospholipid Complex: An Amorphous Pharmaceutical System in Herbal Drug Delivery, Curr Drug Discov Technol., 2011
17. D'Mello P, Rana M, Hepatoprotective activity of Psidiumguajava extract and its phospholipid complex in paracetamol induced hepatic damage in rats, International Journal of Phytomedicine, 2010, 2(1).
18. Wang C, Huang L, pH-sensitive immune-liposomes mediate target-cell-specific delivery and controlled expression of a foreign gene in mouse, Proc Natl., Acad. Sci. USA, 1987, 84: p. 7851-7855.
19. Nakae D, Yamamoto K, Yoshiji H, Kinugasa T, Maruyama H, Farber J, Konishi Y, Liposomeencapsulated superoxide dismutase prevents liver necrosis induced by acetaminophen, Am. J. Pathol., 1990, 136: p. 787-795.
20. Nakac D, Yoshiji H, Mamnuma T, Kinugasa T, Farber J, Konishi Y, Endocytosis-independent uptake of liposome-encapsulated superoxide dismutase prevents the killing of cultured hepatocytes by rerr-butyl hydroperoxide, Arch. Biochem. Biophys., 1990, 279: p. 315-319.
21. Imaizumi S, Woolworth V, Fishman R, Chan P, Liposome-entrapped superoxide dismutase reduces cerebral infarction in cerebral ischemia in rats, Stroke, 1990, 21: p. 1312-1317.
22. Yao T, Esposti D, Huang L, Arnon R, Spangenberger A, Zern M, Inhibition of carbon tetrachlorideinduced liver injury by liposomes containing vitamin E, Am. J. Physiol., 1994, 267: p. G476-G484.
23. Mori A, Klibanov A, TorchilinV, Huang L, Influence of the steric barrier activity of amphipathic poly(ethyleneglyco1) and ganglioside GM1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivo, FEBS Lett., 1991, 284: p. 263-266.
24. Litzinger D, Huang L, Biodistribution and immunetargetablility of ganglioside-stabilized dioleoylphosphatidylethanolamine liposomes, Biochim. Biophys. Acta, 1992, 1104: p. 179-187.
25. Ajazuddin SS, Applications of novel drug delivery system for herbal formulations. Fitoterapia, 2010, 81: p. 680-689.
26. AbrolS, Trehan A, Katare OP, Comparative Study of Different Silymarin Formulations: Formulation, Characterisation and In Vitro/In Vivo Evaluation, Current Drug Delivery, 2005, 2: p. 45-51.
27. Wang J, Tang HF, Shen M, Wang L, Fang KQ, Preparation and quality evaluation of oleanolic acid-loaded solid lipid nanoparticles, J Fourth MilMedUniv, 2007, 28: p. 472-472.
28. Chen Y, Yang XL, Zhao XL, Xu HB, Preparation of oleanolic acid nanosuspension, Chin Pharm J, 2006, 41: p. 924-927.
29. Kumar C, Nanotechnology tools in pharmaceutical R&D, Mater Today, 2010, 12: p. 24-30.
30. Raffa V, Vittorio O, Riggio C, Cuschieri A, Progress in nanotechnology for healthcare, Minim Invasive Ther Allied Technol, 2010, 19: p. 127-135.
31. Mei Z, Chen H, Weng T, Yang Y, Yang X, Solid lipid nanoparticle and microemulsion for topical delivery of triptolide, Eur J Pharm Biopharm, 2003, 56: p. 189-196.
32. Latha S, Selvamani P, Kumar CS, Sharavanan P, Suganya G, Beniwal VS, Rao PR, Formulation development and evaluation of metronidazolemagnetic nanosuspension as a magnetic-targeted and polymeric controlled drug delivery system, J MagnMagn Mater, 2009, 321: p. 1580-1585.
33. Patravale VB, Abhijit AD, KulkarniRM, Nanosuspensions: a promising drug delivery strategy, Journal of Pharmacy and Pharmacology (JPP), 2004, 56: p. 827-840.
34. Gasco MR, Solid lipid nanospheres form warm microemulsions, Pharm. Technol. Eur., 1997, 9: p. 32-42.
35. Wang L, Dong J, Chen J, Eastoe J, Li X, Design and optimization of a new self-nanoemulsifying drug delivery system, J Colloid Interface Sci., 2009, 330: p. 443-448.
36. Meiwan C, Zhangfeng Z, Wen T, Shengpeng W, Yitao W, Recent advances in nanoparticle formulation of oleanolic acid, Chinese Medicine, 2011, 6(20).
37. Yen F, Wu TH, Lin GT, Cham TM, Lin CC, Nanoparticles formulation of Cuscutachinensis prevents acetaminophen-induced hepatotoxicity in rats, Food and Chemical Toxico., 2008, 46: p. 1771-1777.
38. Song Y, Ping QN, Zheng-Hong WU, Preparation of SilybinNanoemulsion and its Pharmacokinetics in Rabbits, Journal of China Pharmaceutical University, 2005.
39. Yanyu X, Yunmei S, Zhipeng C, Quineng P, The preparation of Silybin-phospholipidcomplex and the study on its pharmacokinetics in rats, Int J Pharm, 2006, 307(1): p. 77-82.
40. Chen M, Lipid excipients and delivery systems for pharmaceutical development: a regulatory perspective, Advanced Drug Delivery Reviews, 2008, 60: p. 768-777.
41. Hoet H, Hohlfeld IB, Salata OV, Nanoparticles-known and unknown health risks, Journal of Nanobiotechnology, 2004, 2(12): p. 1-15.
42. Rabinow B, Nanosuspensions in drug delivery, Nat. Rev. Drug Discov., 2004, 3: p. 785-796.